Bluebird Bio Inc. (NASDAQ:BLUE)

CAPS Rating: 4 out of 5

Results 1 - 5 of 5

Recs

0
Member Avatar pchop12316 (81.56) Submitted: 8/27/2014 1:37:03 PM : Outperform Start Price: $38.69 BLUE Score: -0.52

Low PE & building momentum

Recs

0
Member Avatar SkepBioInvestor (95.42) Submitted: 6/26/2014 5:21:15 PM : Outperform Start Price: $39.88 BLUE Score: -6.25

Wall St darling

Recs

1
Member Avatar loangolfer (< 20) Submitted: 1/17/2014 8:43:56 AM : Outperform Start Price: $24.26 BLUE Score: +49.89

ZZ likes it......

Recs

10
Member Avatar zzlangerhans (99.78) Submitted: 8/22/2013 1:17:56 AM : Outperform Start Price: $27.03 BLUE Score: +21.66

There's some companies I study fairly vigorously before I start nattering about them and some I don't. Bluebird falls into the latter category. There's not much I can do - I'm just one guy trying to follow 250 stocks plus I have two babies who think Dad's laptop is the greatest toy in the world. All I can say about Bluebird is that they're developing lentoviral vectors, which I believe are the vectors you use when you've given up other viral vectors for Lent. Bluebird has one trial in progress for a lentoviral gene therapy of beta thalassemia and another planned to begin in mid-2013, and they're planning to initiate a phase II/III trial of another lentoviral gene therapy for childhood cerebral adrenoleukodystrophy in late 2013.

I happen to own 40 shares of Bluebird bought at the absolute all time high of 36 on July 17, courtesy of Portefeuille. I don't mean to razz him too much; that doesn't happen very often. The stock's been in a pretty nasty declining trend since then but I have a feeling things will pick back up before long. Hopefully by then I'll have had time to brush up a little on what this company actually does.

Recs

1
Member Avatar usubanas (99.50) Submitted: 8/21/2013 2:49:52 PM : Outperform Start Price: $25.51 BLUE Score: +30.14

the future is... here

Results 1 - 5 of 5

Featured Broker Partners


Advertisement